HESTERBIO vs LINCOLN: Stock Comparison
HESTER BIOSCIENCES is the larger company by market capitalisation. HESTER BIOSCIENCES shows a higher ROE, a higher dividend yield and faster revenue growth, while LINCOLN PHARMA shows a lower P/E, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
HESTERBIO leads 6; LINCOLN leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | HESTERBIO | LINCOLN |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | HESTERBIO | LINCOLN |
|---|---|---|
| Live Price | ₹2,405.4 | ₹620.8 |
| Day Change | 9.25% | -0.3% |
| Volume | 93,542 | 29,091 |
| 52-Week High | ₹2,683.6 | ₹770 |
| 52-Week Low | ₹1,239.3 | ₹440 |
| Distance from 52W High | -10.37% | -19.38% |
Valuation
| Metric | HESTERBIO | LINCOLN |
|---|---|---|
| Market Cap | ₹2,025 Cr | ₹1,240 Cr |
| P/E Ratio | 14.27x | 12.83x |
| P/B Ratio | 5.4x | 1.63x |
| EPS | ₹17.29 | ₹18.09 |
| Book Value | ₹432.34 | ₹378.25 |
| Dividend Yield | 0.46% | 0.3% |
Growth
| Metric | HESTERBIO | LINCOLN |
|---|---|---|
| Revenue Growth (TTM YoY) | 38.2% | 11.4% |
| EPS Growth (TTM YoY) | 968.7% | 0.6% |
| Qtr Sales Growth | -5.93% | 0% |
| Qtr Profit Growth | -84.79% | 0% |
Profitability & Leverage
| Metric | HESTERBIO | LINCOLN |
|---|---|---|
| ROE | 15.63% | 11.6% |
| ROCE | 9.19% | 11.97% |
| Net Margin | 16.73% | 13.1% |
| Operating Margin | 24.17% | 17.38% |
| Debt to Equity | 0.51x | 0.01x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | HESTERBIO | LINCOLN |
|---|---|---|
| Promoter Holding | 44.28% | 49.78% |
| FII Holding | 0.31%▼ 0.07 pp | 4.6%▼ 0.59 pp |
| DII Holding | 0% | 0.27%▼ 0.82 pp |
| Public Holding | 45.95%▲ 0.06 pp | 45.36%▲ 1.42 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: HESTER BIOSCIENCES and LINCOLN PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.